Skip to Content
Merck
  • Topical administration of tranexamic acid in primary total hip and total knee arthroplasty.

Topical administration of tranexamic acid in primary total hip and total knee arthroplasty.

The Journal of arthroplasty (2013-11-19)
Joseph G Martin, Kevin B Cassatt, Katie A Kincaid-Cinnamon, Denise S Westendorf, Ann S Garton, Jon H Lemke
ABSTRACT

Major blood loss is a known potential complication in total hip and total knee arthroplasty. We conducted a prospective, stratified, randomized, double-blind, placebo-controlled trial that evaluated 100 patients undergoing total knee or total hip arthroplasty to evaluate the effect on blood loss using the topical application of tranexamic acid. Participants received either 2 g of topical tranexamic acid or the equivalent volume of placebo into the joint prior to surgical closure. Tranexamic acid resulted in a lower mean maximum decline in postoperative hemoglobin levels when compared to placebo (P = 0.013). Patients in the tranexamic acid group demonstrated an improved but non-significant reduction in the units of blood transfused compared to placebo (P = 0.423). There was no clinically significant increase in complications in the tranexamic acid group, including no incidence of venous thromboembolism.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
trans-4-(Aminomethyl)cyclohexanecarboxylic acid, 97%
USP
Tranexamic acid, United States Pharmacopeia (USP) Reference Standard
Tranexamic acid, European Pharmacopoeia (EP) Reference Standard